This site is intended for health professionals only!

Published on 26 May 2009

Share this story:

Amgen acquires heart-drug rights

teaser

UK biotech company Amgen is acquiring the rights to Cytokinetics’s experimental heart drug CK-1827452 at present being trialled for the treatment of heart failure.

Amgen will pay $50 million (£31.6m) upfront and up to $600 million in the future, depending on the drug’s success. CK-1827452 is a novel, small-molecule, direct activator of cardiac myosin, the motor protein that causes cardiac contraction.

Amgen had earlier paid $75m for the option to the drug, and decided to exercise the option after seeing more clinical data, according to the New York Times.

Copyright Press Association 2009

CK-1827452



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: